Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cobra venom in preparation of medicament for treating chronic obstructive pulmonary disease

A technology for chronic obstructive pulmonary disease and cobra snake venom, which is applied in drug combinations, respiratory diseases, and pharmaceutical formulations. effect of effect

Inactive Publication Date: 2015-03-25
SUZHOU RENBEN PHARMA
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

With the deepening of research, snake venom and its products have been applied clinically. In addition to the analgesic effect, research has found that it has good curative effects in anti-rheumatism, anti-tumor and treatment of nervous system diseases. The role of lung disease has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cobra venom in preparation of medicament for treating chronic obstructive pulmonary disease
  • Application of cobra venom in preparation of medicament for treating chronic obstructive pulmonary disease
  • Application of cobra venom in preparation of medicament for treating chronic obstructive pulmonary disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] The animal pharmacodynamic experiment of embodiment 1 cobra venom

[0037] Effects of cobra snake venom on acute pneumonia in mice induced by initial exposure to lipopolysaccharide:

[0038] Lipopolysaccharide (LPS) is a component in the cell wall of Gram-negative bacteria, which can cause various inflammatory reactions in the body. A single administration of lipopolysaccharide 5mg / kg can make a mouse model of acute pneumonia. Kunming mice were randomly divided into 5 groups (n=10) half and half female, body weight 18-22g: normal saline control group, model group, small dose of Chinese cobra snake venom heating group (30 μg / kg), medium dose group (90 μg / kg), high dose group ( 270 μg / kg). After administration of lipopolysaccharide (5 mg / kg), observe the animal's activity state and respiratory rate. In the test of cobra snake venom in treating lipopolysaccharide-induced acute lung injury in mice, the embodiment adopts intragastric administration, and the dosage is 10-3000...

Embodiment 2

[0045] Example 2 Cobra snake venom effect experiment on chronic obstructive pneumonia induced by repeated administration of LPS

[0046] In the experiment, lipopolysaccharide 5mg / kg was given once a week, and the repeated administration was repeated for 8 weeks to make a mouse model of chronic obstructive pneumonia. The Kunming mice were randomly divided into 5 groups (n=10) with half and half females, weighing 18-22g : Physiological saline control group, model group, low-dose Chinese cobra venom heating group (30 μg / kg), medium-dose group (90 μg / kg), high-dose group (270 μg / kg). During the long-term administration, the activity state and respiratory rate of the animals were observed. In the experiment of treating lipopolysaccharide-induced chronic obstructive pneumonia in mice with Chinese cobra venom, the embodiment adopts intragastric administration, and the dosage is 10-3000 μg / kg, once a day.

[0047] Eight weeks after the experiment, the mice were removed from the eyeba...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicaments, and particularly relates to an application of cobra venom in preparation of a medicament for treating chronic obstructive pulmonary disease. The cobra venom has an obvious treatment effect on chronic obstructive pneumonia induced by repeatedly contacting LPS (lipopolysaccharide) for a long term, and can effectively improve the pathological injury of lung tissues. The Chinese cobra venom not only can reduce the lung coefficient of a chronic obstructive pneumonia mouse, but also can effectively protect the lung tissues. The cobra venom not only can inhibit the degradation of IkB-alpha in the lung tissues of a sick mouse, but also can lower the expression of TGF-beta1. The cobra venom not only can reduce the TNF-alpha level, but also can reduce the level of an inflammatory factor IL-1.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to the application of cobra snake venom in the preparation of medicines for treating chronic obstructive pulmonary disease. Background technique [0002] Chronic obstructive pulmonary disease is a chronic respiratory disease characterized by airflow obstruction, with a large number of patients, and its mortality rate is now the fourth leading cause of death in the world, and it has a tendency to increase year by year. Smoking or exposure to smoke is the leading cause of COPD. Another important factor in the occurrence, development and evolution of chronic obstructive pulmonary disease is repeated respiratory tract infection. Lipopolysaccharide (LPS) is an endotoxin in the cell wall of Gram-negative bacteria and a major cause of respiratory tract infection. Inducing factors, present in smog and air, can stimulate the body to produce inflammatory factors such as IL-1 and TNF-α, cau...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/583A61K38/17A61P11/00
CPCA61K35/583A61K38/17
Inventor 秦正红崔奎寇建群
Owner SUZHOU RENBEN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com